Targeted intracellular delivery of Cas13 and Cas9 nucleases using bacterial toxin-based platforms

Cell Rep. 2022 Mar 8;38(10):110476. doi: 10.1016/j.celrep.2022.110476.

Abstract

Targeted delivery of therapeutic proteins toward specific cells and across cell membranes remains major challenges. Here, we develop protein-based delivery systems utilizing detoxified single-chain bacterial toxins such as diphtheria toxin (DT) and botulinum neurotoxin (BoNT)-like toxin, BoNT/X, as carriers. The system can deliver large protein cargoes including Cas13a, CasRx, Cas9, and Cre recombinase into cells in a receptor-dependent manner, although delivery of ribonucleoproteins containing guide RNAs is not successful. Delivery of Cas13a and CasRx, together with guide RNA expression, reduces mRNAs encoding GFP, SARS-CoV-2 fragments, and endogenous proteins PPIB, KRAS, and CXCR4 in multiple cell lines. Delivery of Cre recombinase modifies the reporter loci in cells. Delivery of Cas9, together with guide RNA expression, generates mutations at the targeted genomic sites in cell lines and induced pluripotent stem cell (iPSC)-derived human neurons. These findings establish modular delivery systems based on single-chain bacterial toxins for delivery of membrane-impermeable therapeutics into targeted cells.

Keywords: CRISPR-Cas9; Cas13; Cas9; Cre; SARS-CoV-2; botulinum neurotoxin; diphtheria toxin; genome editing; intracellular delivery; toxin.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Bacterial Toxins* / genetics
  • COVID-19*
  • CRISPR-Cas Systems
  • Gene Editing
  • Humans
  • RNA, Guide, CRISPR-Cas Systems / metabolism
  • SARS-CoV-2

Substances

  • Bacterial Toxins
  • RNA, Guide, CRISPR-Cas Systems